Posts tagged "Biotech"

Penny Stock News: Marina Biotech, Inc. (MRNA: OTCQB) | Marina Biotech to Present at the 9th Annual LD Micro Main Event

BOTHELL, WA–(Marketwired – Nov 25, 2016) – Marina Biotech, Inc. (OTCQB: MRNA) today announced that its CEO, Joseph W. Ramelli, will be presenting at the LD Micro Main Event on Thursday, December 8, 2016 at 8am PT, at the Luxe Sunsent Boulevard Hotel in Los Angeles.  Management will update investors on the synergy derived from the recent merger with IthenaPharma to deliver unparalleled targeted therapy against colorectal cancer as well as familial adenomatous polyposis (FAP).  In addition, Mr. Ramelli and Marina Biotech’s chairman, Dr. Vuong Trieu, will participate in 1-on-1 meetings with conference attendees. A copy of the investor presentation will be accessible in the investor relations section of the company’s website at http://www.marinabio.com/investors/. About Marina Biotech, Inc. Marina Biotech is a clinical stage development and commercialization company, with a pipeline focused on treating familial adenomatous polyposis (FAP) and colon cancer. In addition, Marina has a preclinical program for myotonic dystrophy, using its own unique antisense oligonucleotide chemistry and delivery capabilities. Marina Biotech Forward-Looking Statements Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially […]

Read more...

Posted by admin - November 25, 2016 at 1:08 pm

Categories: Latest Penny Stock News   Tags: , , , , , , , , , , , ,

Penny Stock News: Oncology Biotech Standout MabVax Therapeutics Interviewed on Small Cap Nation

Contact Us Journalists Blog Log In Sign Up Send a Release News in Focus Business & Money Science & Tech Lifestyle & Health Policy & Public Interest People & Culture Sep 15, 2016, 08:00 ET Preview: MabVax Therapeutics Provides Webcast Presentation at Rodman & Renshaw Conference Release contains wide tables.View fullscreen. News in Focus Browse News Releases Multimedia Gallery Trending Topics Business & Money Auto & Transportation Business Technology Entertain­ment & Media Financial Services & Investing General Business Science & Tech Consumer Technology Energy Environ­ment Heavy Industry & Manufacturing Telecomm­unications Lifestyle & Health Consumer Products & Retail Entertain­ment & Media Health Sports Travel Policy & Public Interest People & Culture News in Focus Business & Money Science & Tech Lifestyle & Health Policy & Public Interest People & Culture PR Newswire: OTC, SmallCap

Read more...

Posted by admin - September 16, 2016 at 1:41 pm

Categories: Latest Penny Stock News   Tags: , , , , , , , , , ,

Penny Stock News: Oncolytics Biotech Inc. (ONCYF: OTCQX International) | Oncolytics Biotech® Inc. Announces First Patients Treated in Phase 1b Study in Advanced Pancreatic Cancer

CALGARY, Jan. 19, 2016 /PRNewswire/ – Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, OTCQX:ONCYF) today announced that the first patients have been treated  in a Phase 1b study of pembrolizumab (KEYTRUDA®) in combination with REOLYSIN® (pelareorep) and chemotherapy in patients with advanced pancreatic adenocarcinoma (REO 024).  “Checkpoint inhibitors are an emerging class of therapeutic that allows the immune system to better recognize and target tumors, and the goal of this study is to assess their potential in combination with REOLYSIN®,” said Dr, Brad Thompson, President and CEO of Oncolytics. “Based on our early research it is possible that checkpoint inhibitors could support improved survival outcomes for patients treated with oncolytic viral therapy.” The study is enrolling patients 18 years or older with histologically confirmed advanced or metastatic pancreatic adenocarcinoma who have failed, or did not tolerate, first line treatment. It is an open-label Phase Ib trial designed to determine the safety and dose-limiting toxicities of REOLYSIN® and chemotherapy (gemcitabine or irinotecan or fluorouracil, at the treating physician’s preference) in combination with pembrolizumab. Secondary endpoints include overall response rate and progression free survival by immune-related response criteria; overall survival; and effects of REOLYSIN® and pembrolizumab when administered in combination as determined by analysis of […]

Read more...

Posted by admin - January 20, 2016 at 5:57 pm

Categories: Latest Penny Stock News   Tags: , , , , , , , , , , , , , , , , , ,

Penny Stock News: Oncolytics Biotech Inc. (ONCYF: OTCQX International) | Oncolytics Biotech® Inc. Announces First Patients Treated in Phase 1b Study in Advanced Pancreatic Cancer

CALGARY, Jan. 19, 2016 /CNW/ – Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, OTCQX:ONCYF) today announced that the first patients have been treated  in a Phase 1b study of pembrolizumab (KEYTRUDA®) in combination with REOLYSIN® (pelareorep) and chemotherapy in patients with advanced pancreatic adenocarcinoma (REO 024).  “Checkpoint inhibitors are an emerging class of therapeutic that allows the immune system to better recognize and target tumors, and the goal of this study is to assess their potential in combination with REOLYSIN®,” said Dr, Brad Thompson, President and CEO of Oncolytics. “Based on our early research it is possible that checkpoint inhibitors could support improved survival outcomes for patients treated with oncolytic viral therapy.” The study is enrolling patients 18 years or older with histologically confirmed advanced or metastatic pancreatic adenocarcinoma who have failed, or did not tolerate, first line treatment. It is an open-label Phase Ib trial designed to determine the safety and dose-limiting toxicities of REOLYSIN® and chemotherapy (gemcitabine or irinotecan or fluorouracil, at the treating physician’s preference) in combination with pembrolizumab. Secondary endpoints include overall response rate and progression free survival by immune-related response criteria; overall survival; and effects of REOLYSIN® and pembrolizumab when administered in combination as determined by analysis of […]

Read more...

Posted by admin - January 20, 2016 at 6:11 am

Categories: Latest Penny Stock News   Tags: , , , , , , , , , , , , , , , , , ,

Penny Stock News: Mr. James Mellon and Dr. Gregory Bailey (“Offerors”) Announce Additional Shares in Portage Biotech Inc. (Portage)

TORONTO, Dec. 14, 2015 /PRNewswire/ – The Offerors, announced that they have acquired an aggregate of 494,000 common shares of Portage. These common shares represent approximately 0.2% of the issued and outstanding common shares of Portage (based upon the 245,438,894 common shares stated to be issued and outstanding as at November 24, 2015, by Portage in its management’s discussion and analysis for the three months ended September 30, 2015 (the “Q2 MD&A”) filed on SEDAR on November 26, 2015. These common shares were purchased by the Offerors through the facilities of the OTC Markets and CSE for an average price of $ 0.13 (US$ 0.098) per share. After giving effect to the purchases described in Section (2) above, Offerors now have ownership and control over 85,078,042 common shares of Portage, representing approximately 34.66% of the outstanding common shares of Portage (based upon 245,438,894 common shares stated to be issued and outstanding as at November 24, 2015 by Portage in the Q2 MD&A). After giving effect to the purchases noted above, Offerors, together with another joint actor, Dr. Declan Doogan, now have ownership and control over 113,389,110 common shares of Portage, representing approximately 46.20% of the outstanding common shares of Portage (based upon […]

Read more...

Posted by admin - December 15, 2015 at 1:22 am

Categories: Latest Penny Stock News   Tags: , , , , , , , , , , , , ,

Penny Stock News: Sangui BioTech International, Inc. (SGBI: OTCQB) | Sangui Biotech: Sluggish Revenue Development Continues / Comprehensive Cost Containment Program under Preparation / Joachim Fleing Stepped Down

Sangui Biotech: Sluggish Revenue Development Continues / Comprehensive Cost Containment Program under Preparation / Joachim Fleing Stepped Down Oct 28, 2015 OTC Disclosure & News Service – According to preliminary, unaudited figures Sangui Biotech International, Inc. yielded revenues from royalties and product sales of around USD12,000 in the course of the first three months of its 2016 financial year, ended September 30, 2015. In the first quarter of the 2015 financial year (ended September 30, 2014) revenues amounted to USD73,740 due to one large order. According to information provided by global licensee SastoMed GmbH a significant increase in revenues is not to be expected until the years 2017/2018. The Board of Directors currently works on a comprehensive cost containment concept in order to adapt the ongoing expenses to the overall income. Research and development, also in view of the SBT102 and SBT1001 projects, will be under review and stalled if necessary until separate project financing will become available. Dr. Joachim Fleing stepped down from his positions as a Director and Officer of the Company on October 27, 2015, with immediate effect. For an interim period he has offered to assist the Company with the ongoing accounting, compliance and stock related […]

Read more...

Posted by admin - October 28, 2015 at 11:26 am

Categories: Latest Penny Stock News   Tags: , , , , , , , , , , , , , , , , , , , , , ,

Penny Stock News: PharmaCyte Biotech, Inc. (PMCB: OTCQB) | PharmaCyte Biotech Due Diligence Report – Technology Gets an Industry Boost – Small Cap Street

NEW YORK, Oct. 27, 2015 /PRNewswire/ — PharmaCyte Biotech, Inc. (OTCQB: PMCB) shares closed at $ .10 off 5.66% in yesterday’s session. Trading volume was 3 million shares, somewhat over the daily average of 2 million shares traded. PMCB shares had jumped 75% from mid-September to mid-October before investors took some profits over the past two weeks. Our due diligence will show investors in PharmaCyte Biotech, information they need about the company’s Cell-in-a-Box technology platform to make investment choices. Get our brief report at the link below. http://bit.ly/__PMCB_Due_Diligence_Report Copy and paste to browser may be required. About PharmaCyte Biotech, Inc. PharmaCyte Biotech, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology, known as Cell-in-a-Box. Its patented Cell-in-a-Box technology would be used as a platform to build treatments for various types of cancer, including advanced, inoperable pancreatic cancer, and diabetes. FORWARD-LOOKING DISCLAIMER    This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. […]

Read more...

Posted by admin - October 27, 2015 at 1:01 pm

Categories: Latest Penny Stock News   Tags: , , , , , , , , , , , , , , ,

Penny Stock News: PharmaCyte Biotech, Inc. (PMCB: OTCQB) | PharmaCyte Biotech’s Encapsulation Technology Could Address Unmet Medical Need

PharmaCyte Biotech’s Encapsulation Technology Could Address Unmet Medical Need Sep 28, 2015 OTC Disclosure & News Service – SILVER SPRING, Md., Sept. 28, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, released today the second in a series of articles that will serve to educate the public on its technology and how it is used in the treatment of advanced pancreatic cancer. This latest article, written by Dr. Matthias Löhr of the famed Karolinska Institute in Stockholm, Sweden, and the Chairman of PharmaCyte Biotech’s Scientific Advisory Board, discusses the unmet clinical need of a large group of patients suffering from locally advanced pancreatic cancer. PharmaCyte Biotech’s Chief Executive Officer, Kenneth L. Waggoner, commented on Dr. Löhr’s article, “Dr. Löhr understands the severity of the unmet medical need he addresses in his article as much as anyone. Dr. Löhr explains his rationale for believing there is an urgent need to develop a therapy for patients with pancreatic cancer that is not currently being addressed by the medical community. Our other prominent oncologists also believe that new therapeutic options are needed for […]

Read more...

Posted by admin - September 28, 2015 at 2:01 pm

Categories: Latest Penny Stock News   Tags: , , , , , , , , , , , , , , ,

Penny Stock News: DanDrit Biotech USA, Inc. Announces Final Collaboration Agreement with the GISCAD Foundation

COPENHAGEN, Denmark, April 28, 2015 /PRNewswire/ — DanDrit Biotech USA, Inc. (“DanDrit”) (OTC:DDRT), a biotechnology company developing a vaccine for the treatment of colorectal cancer, is pleased to announce that it has signed a final collaboration agreement with GISCAD Foundation, a highly recognized Italian group with a focus on digestive tract cancer studies. The collaboration relates to VIVA, a Phase III adjuvant trial of DanDrit vaccine, in patients with no evidence of disease (NED) Stage IV colorectal cancer (CRC). The primary aim of the VIVA clinical trial is to evaluate the ability of MelCancerVac™ (MCV) to prevent a relapse in Stage IV CRC patients rendered disease free after completion of standard treatment according to local practices.  Professor Alberto Sobrero (see below) will be the Principal Investigator of this randomized multicenter study. Dr. Eric Leire, CEO of DanDrit Biotech, stated, “We are honored to collaborate with the GISCAD Foundation for our VIVA Phase III trial.  Its impressive experience in managing clinical trials with advanced colorectal cancer patients is highly valuable to us.  We understand that it takes partnerships across institutions, across industries, and across the world to insure that every cancer patient is given the best therapy to improve their outcome. Additionally, […]

Read more...

Posted by admin - April 28, 2015 at 1:32 pm

Categories: Latest Penny Stock News   Tags: , , , , , , , , , , ,

Penny Stock News: PharmaCyte Biotech Moving Closer to Human Clinical Trials Around an Elite New Leadership Team

BALTIMORE, Apr, 22, 2015 /PRNewswire/ — Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has issued a new sponsored research article on PharmaCyte Biotech, Inc. (OTCQB – PMCB), a publicly traded, clinical stage biotechnology company focused on developing and preparing treatments for cancer and diabetes. To view the sponsored research article, along with disclosures and disclaimers, or to download it and previous articles in their entirety, please visit www.GoldmanResearch.com.  In the update, analyst Rob Goldman discusses the Company’s elite new leadership team and how they help set the stage for future human clinical trials for diabetes and cancer. “One of the untold stories regarding the recent transformation of PharmaCyte Biotech (OTCQB – PMCB) is that in the span of just over a year, CEO Kenneth L. Waggoner has significantly upgraded the quality of the Company’s leadership team, particularly with respect to the clinical research and execution side, which is a veritable “Who’s Who” in the global scientific and pharmaceutical community.” “The Company recently announced that Thomas Liquard has joined its Board of Directors and will become Chairman of the Audit Committee. Mr. Liquard formerly served as Senior […]

Read more...

Posted by admin - April 22, 2015 at 6:18 pm

Categories: Latest Penny Stock News   Tags: , , , , , , , , , , , , ,

Next Page »